ABL Bio Valuation

Q: What is the Fair Price of A298380 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

A298380 (₩27650) is trading above our estimate of [[fair value]] (₩3855.78)

Is A298380 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A298380 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A298380 (₩27650) is trading above our estimate of fair value (₩3855.78)

Significantly Below Fair Value: A298380 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A298380?

Key metric: As A298380 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A298380. This is calculated by dividing A298380's market cap by their current revenue.
What is A298380's PS Ratio?
PS Ratio	41.1x
Sales	₩32.32b
Market Cap	₩1.39t

A298380 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	45.1x
Enterprise Value/EBITDA	-30.4x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does A298380's PS Ratio compare to its peers?

The above table shows the PS ratio for A298380 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	19.4x
A006280 GC Biopharma	0.9x	8.8%	₩1.5t
A007390 NatureCellLtd	59.1x	n/a	₩1.7t
A086900 Medy-Tox	3.5x	12.5%	₩856.2b
A115450 HLB TherapeuticsLtd	13.9x	n/a	₩838.7b
A298380 ABL Bio	41.1x	25.5%	₩1.3t

Price-To-Sales vs Peers: A298380 is expensive based on its Price-To-Sales Ratio (41.1x) compared to the peer average (19.4x).

Price to Sales Ratio vs Industry

How does A298380's PS Ratio compare vs other companies in the KR Biotechs Industry?

27 Companies	Price / Sales	Estimated Growth	Market Cap
A006280 GC Biopharma	0.9x	8.8%	US$1.10b
A096530 Seegene	2.6x	15.7%	US$754.39m
A086900 Medy-Tox	3.5x	12.5%	US$613.05m
A005250 Green Cross Holdings	0.3x	n/a	US$463.68m

27 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: A298380 is expensive based on its Price-To-Sales Ratio (41.1x) compared to the KR Biotechs industry average (9.5x).

Price to Sales Ratio vs Fair Ratio

What is A298380's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A298380 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	41.1x
Fair PS Ratio	7.8x

Price-To-Sales vs Fair Ratio: A298380 is expensive based on its Price-To-Sales Ratio (41.1x) compared to the estimated Fair Price-To-Sales Ratio (7.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A298380 forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	₩27,650.00	₩44,750.00 +61.8%	21.0%	₩60,000.00	₩37,000.00	n/a	4
Nov ’25	₩35,850.00	₩44,750.00 +24.8%	21.0%	₩60,000.00	₩37,000.00	n/a	4
Oct ’25	₩31,000.00	₩38,750.00 +25.0%	9.4%	₩45,000.00	₩36,000.00	n/a	4
Sep ’25	₩34,600.00	₩38,750.00 +12.0%	9.4%	₩45,000.00	₩36,000.00	n/a	4
Aug ’25	₩29,200.00	₩36,500.00 +25.0%	1.4%	₩37,000.00	₩36,000.00	n/a	4
Jul ’25	₩24,450.00	₩36,666.67 +50.0%	1.3%	₩37,000.00	₩36,000.00	n/a	3
Jun ’25	₩22,650.00	₩36,666.67 +61.9%	1.3%	₩37,000.00	₩36,000.00	n/a	3
May ’25	₩26,000.00	₩36,666.67 +41.0%	1.3%	₩37,000.00	₩36,000.00	n/a	3
Apr ’25	₩27,400.00	₩36,666.67 +33.8%	1.3%	₩37,000.00	₩36,000.00	n/a	3
Mar ’25	₩22,800.00	₩36,500.00 +60.1%	1.4%	₩37,000.00	₩36,000.00	n/a	2
Feb ’25	₩21,800.00	₩36,500.00 +67.4%	1.4%	₩37,000.00	₩36,000.00	n/a	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

J2KBIO

₩53.0b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,270.00

-2.5%

n/a

Medy-Tox

₩856.2b

Operates as a biopharmaceutical company in South Korea.

A086900

₩127,200.00

1.0%

-42.2%

Hugel

₩3.0t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩277,500.00

1.3%

76.0%